stockrow
Saturday 7 November 2026
Export VBIO’s income statement to Excel — free account
Valion Bio, Inc.
VBIO Healthcare Biotechnology
Valion Bio, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $780,000.00, down 33.7% from fiscal 2023.
- Revenue
- +15.9%
- EPS
- +0.91%
- Free cash flow
- −189.0%
Quarter to June 2026, against a year earlier
0.51
0.01
+2.00%
Follow VBIO
Alert me
Valion Bio, Inc. (VBIO) P/E ratio
Valion Bio, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| Dec 2024 | 0.0× | — |
| 17 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BBLG Bone Biologics Corp. compare | n/m |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR compare | n/m |
| ARTL Artelo Biosciences, Inc. compare | n/m |
| MTNB Matinas Biopharma Holdings, Inc. compare | n/m |
| VBIO Valion Bio, Inc. | n/m |
| LABT Lakewood-Amedex Biotherapeutics Inc. compare | n/m |
| JAGX Jaguar Animal Health, Inc. compare | n/m |
| BPTH Bio-Path Holdings, Inc. compare | n/m |
| PTIX Atrinsic Inc. compare | 0.2× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)